Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Repros Therapeutics Inc.
This is an extension of the phase II, three-arm, parallel design, dose-ranging, placebo-controlled, randomized, double-blind, multicenter study in which placebo or one (1) of two (2) dose levels of Proellex® was administered once-daily for four (4) months.
Age
18–48
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Only subjects treated in the ZPE-201 study will be allowed to enter the extension study.
Subjects who withdrew from ZPE-201 due to lack of treatment efficacy will also be invited to participate.
You may not be if
All other subjects
Clareo Health | Study Evaluating the Safety and Efficacy of Proellex® in the Treatment of Endometriosis-extension Study
